NASDAQ:SYBXSynlogic Stock Price, Forecast & News

Synlogic's stock was trading at $1.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SYBX shares have increased by 33.8% and is now trading at $2.06. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Synlogic.

Synlogic is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Synlogic.

Synlogic Inc (NASDAQ:SYBX) issued its quarterly earnings results on Friday, May, 8th. The biotechnology company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by $0.03. The biotechnology company earned $0.10 million during the quarter, compared to analyst estimates of $0.73 million. Synlogic had a negative net margin of 2,733.25% and a negative return on equity of 33.46%. View Synlogic's earnings history.

Synlogic's stock reverse split on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.

6 Wall Street analysts have issued 12 month price targets for Synlogic's shares. Their forecasts range from $2.00 to $25.00. On average, they expect Synlogic's stock price to reach $13.40 in the next twelve months. This suggests a possible upside of 550.5% from the stock's current price. View analysts' price targets for Synlogic.

Headlines about SYBX stock have trended negative this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Synlogic earned a daily sentiment score of -2.1 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Synlogic.

Synlogic saw a decline in short interest in the month of June. As of June 30th, there was short interest totaling 502,900 shares, a decline of 25.5% from the June 15th total of 674,700 shares. Based on an average trading volume of 288,700 shares, the days-to-cover ratio is currently 1.7 days. Approximately 2.7% of the company's shares are short sold. View Synlogic's Current Options Chain.

Some companies that are related to Synlogic include ProQR Therapeutics (PRQR), Abeona Therapeutics (ABEO), IVERIC bio (ISEE), Verrica Pharmaceuticals (VRCA), OptiNose (OPTN), Northwest Biotherapeutics (NWBO), MediciNova (MNOV), Verastem (VSTM), REDHILL BIOPHAR/S (RDHL), Selecta Biosciences (SELB), CymaBay Therapeutics (CBAY), Hookipa Pharma (HOOK), Agile Therapeutics (AGRX), TAIWAN LIPOSOME/S (TLC) and Kalvista Pharmaceuticals (KALV). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Synlogic investors own include Reata Pharmaceuticals (RETA), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), SCYNEXIS (SCYX) and Verastem (VSTM).

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SYBX stock can currently be purchased for approximately $2.06.

Synlogic has a market capitalization of $67.65 million and generates $2.22 million in revenue each year. The biotechnology company earns $-51,370,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis. Synlogic employs 74 workers across the globe.

The official website for Synlogic is www.synlogictx.com.

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected]gictx.com.